The FDA on April 28, 2020 granted accelerated approval to a new dosing regimen of 400 mg every six weeks for KEYTRUDA® across all currently approved adult indications, in addition to the current 200 mg every three weeks dosing regimen. KEYTRUDA® is a product of Merck&Co.
Bottom Ad
Advertisement
Subscribe
